precision medicine

Research in Review

Trastuzumab Cost Effectiveness Varies Based on Hormone Receptor Status

09/06/2016

JCP Editors

How cost effective trastuzumab is for human epidermal growth factor receptor 2 (HER2)-positive breast cancer depends largely on patients’ age and hormone receptor status, according to a review published in PLOS...

How...

09/06/2016

Journal of Clinical Pathways

Research in Review

Immune Signatures Predict Treatment Response for Melanoma

09/01/2016

JCP Editors

Adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment may be used to predict patient response to melanoma immunotherapy, according to a study published in Cancer...

...

09/01/2016

Journal of Clinical Pathways

Research in Review

Leptomeningeal Metastases More Common in EGFR+ Lung Cancer

08/17/2016

JCP Editors

Leptomeningeal metastases (LM) incidence is far more common in patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations and is best treated with targeted tyrosine kinase...

...

08/17/2016

Journal of Clinical Pathways

Research in Review

Tumor Genetics Can Change During Treatment for ER+ Breast Cancer

08/12/2016

JCP Editors

Treating human estrogen-receptor (ER)-positive breast cancer tumors with estrogen-deprivation therapy can change the spectrum of mutations in the tumor population, affecting treatment response, according to research...

...

08/12/2016

Journal of Clinical Pathways

Quiz

Friday Morning Quiz ‚Äì Week of August 1-7

08/04/2016

JCP Editors

Results of a phase III study assessing the effectiveness of biosimilar ABP 980 found that it was not inferior to which of the following drugs for the treatment of human epidermal growth factor receptor 2...

...

08/04/2016

Journal of Clinical Pathways

Research in Review

Indicators of Radiotherapy Toxicity Identified

08/03/2016

JCP Editors

A study looking at the genetic information of more than 1500 patients with prostate cancer has identified two variants linked to increased risk of radiotherapy side effects. Used in nearly 50% of patients with...

A...

08/03/2016

Journal of Clinical Pathways

Research in Review

Vemurafenib Improves Response in Patients With Thyroid Cancer

07/28/2016

JCP Editors

Vemurafenib, a drug originally approved for use in patients with BRAF-positive melanoma, has also shown promising anti-tumor activity in some patients harboring this same mutation in thyroid cancer, according to the...

...

07/28/2016

Journal of Clinical Pathways

Interview

The Potentials and Barriers of Precision Medicine in Oncology

06/20/2016

In the mid-1980s, cancer researchers shifted their focus from determining the location of a cancer to identifying the genetic mutations that create it.1 This shift gave birth to a new field of study known as...

In the...

06/20/2016

Journal of Clinical Pathways

Quiz

Friday Quiz ‚Äì Week of June 13-19

06/16/2016

JCP Editors

Monotherapy with which of the following drugs was found to improve response in patients with chronic lymphocytic leukemia after relapsing or becoming refractory to ibrutinib or...

...

06/16/2016

Journal of Clinical Pathways

Nivolumab Effective for Advanced Bladder Cancer

06/07/2016

JCP Editors

Nivolumab may help to significantly reduce tumor burden in patients with metastatic bladder cancer, regardless of whether their tumors have a biomarker related to the drug’s target, according to clinical trial...

...

06/07/2016

Journal of Clinical Pathways